Certain psychiatric treatments require both the healthcare provider and patient to enroll in a Risk Evaluation and Mitigation Strategy (REMS) program before they are administered. Below are links to enroll:

Brexanolone (Zulresso)
http://www.zulressorems.com/

Buprenorphine-based therapies (Suboxone, Subutex)
https://www.samhsa.gov/medication-assisted-treatment/training-materials-resources/buprenorphine-waiver

Clozapine (Clozaril)
https://www.clozapinerems.com/

Esketamine (Spravato)
https://www.spravatorems.com/

Flibanserin (Addyi)
https://addyirems.com/